Eva Hofsli

Trondheim, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Common sense in cancer care.

Common sense in cancer care.

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: August 20, 2026

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data.

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data.

Journal: ImmunoTargets and therapy

Published: January 09, 2026

Serum miRNA Signatures in Cancer Cachexia Depend on Systemic Inflammation.

Serum miRNA Signatures in Cancer Cachexia Depend on Systemic Inflammation.

Journal: Current oncology (Toronto, Ont.)

Published: October 06, 2025

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.

Journal: International journal of cancer

Published: September 10, 2025

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.

Journal: British journal of cancer

Published: August 13, 2025

Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.

Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.

Journal: British journal of cancer

Published: July 14, 2025

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.

Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.

Journal: British journal of cancer

Published: January 27, 2025

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

Journal: Oncoimmunology

Published: July 02, 2024

Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients.

Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients.

Journal: Molecular cancer

Published: April 08, 2024

Can circulating microRNAs predict colorectal cancer? Results from a nested case-control study of pre-diagnostic serum samples from two prospective biobanks.

Can circulating microRNAs predict colorectal cancer? Results from a nested case-control study of pre-diagnostic serum samples from two prospective biobanks.

Journal: BMC cancer

Published: March 19, 2024

Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.

Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.

Journal: British journal of cancer

Published: December 20, 2023

First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.

First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.

Journal: British journal of cancer

Published: December 14, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026